摘要：我爱记歌词...

放羊的星星

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

纸牌屋第二季

A | 战鼓催征，积势蓄力。抚顺渼瑞石油化工有限公司丙烯酰胺聚合物项目现场一派火热。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。10月9日，记者乘车到位于抚顺高新区的项目现场采访，远远就看到穿梭往来的运输车辆和长臂伸展的塔机、起重器等大型设备。　　“现在土建工程基本结束，已经进入钢结构和设备安装阶段。我们以打造精品工程为目标，精心组织，科学施工，紧盯时间节点，正抢抓工期、挂图作战，力争12月底完工。”项目经理闫家兴正忙着推进工程进展，他递给记者一个安全帽，带记者走进项目建设的核心区。今年3月，一季度重点项目集中开工仪式在这里举行时，这里还是一片平整的土地，仅仅7个月时间，办公楼、库房、中控室、实验室等主体拔地而起，140多名工人正在各自岗位上奋战。　　抚顺渼瑞石油化工有限公司成立于2021年，是由爱森（中国）絮凝剂有限公司和天津宝澄生物技术发展有限公司合资建设，项目总投资3.86亿元，主要生产丙烯酰胺聚合物、丙烯酰胺。丙烯酰胺聚合物被誉为“百业助剂”，应用于饮用水生产、工业和城市废水处理、石油化工、采矿、造纸、农业、纺织、个人护理等领域，受益于产业政策支持，未来发展空间广阔。据统计，2020年全球丙烯酰胺聚合物市场规模为39.22亿美元，预计2026年，市场规模将超过88.72亿美元。　　爱森集团是一家致力于全球水处理、水循环和水资源保护的专业化工集团公司，是水溶性丙烯酰胺类聚合物生产的世界领导者，其产量占世界总产量的42%，单体产量占世界总产量的50%，业务覆盖超过全球140个国家。依托爱森集团专利技术，抚顺渼瑞将以降低用水和能源消耗、减少碳足迹作为使命，项目建成后，将形成年产10万吨丙烯酰胺聚合物和5万吨丙烯酰胺产能规模，预计年营业收入12.5亿元，年缴税额4215万元，实现经济效益、社会效益和环境效益同步和谐发展。　　项目建设期间，各级政府全面落实各项惠企政策，不遗余力破解企业发展瓶颈，全力打造优质营商环境。抚顺高新区为企业提供全流程服务，落实项目要素保障，积极联系环保、建设、规划、电力等部门和单位，加快协调施工污水排放、规划手续、用电、图纸审核、设施配套等事宜，为项目早日完工创造有利条件，让“百业助剂”项目早日投产，为打赢攻坚之年攻坚之战贡献力量。